Biotic innovation tackles iron deficiency in women - now recognized across three continents

Contributed by: PR Newswire

Images

PR Newswire associated0
PR Newswire associated1

Tags

BIOTIC-iron-probiotic

More Like This

PR Newswire associated0

BioFlag Showcases Innovative Probiotic Solutions at Vitafoods Europe 2025

PR Newswire associated0

PROBIOS TO ACQUIRE 100 % OF BIOTOBIO

PR Newswire associated0

Angel Yeast Expands into Probiotics R&D and Production, Advances Biotech Transformation

PR Newswire associated0

Angel Group's First Industrialized Strain of Probiotics Anchors Strategic Transformation Towards Biotechnology

HeiQ advances synbiotic cleaning as a sustainable solution to antimicrobial resistance

Human-Residential Bifidobacteria (HRB) strains such as Bifidobacterium longum BB536, B. breve M-16V, B. breve MCC1274, and B. infantis M-63, significantly reduced the concentration of indole produced by Escherichia coli, a known indole producer (Figure 1). Subsequently, the research demonstrated that HRB strains can convert the potentially harmful indole into tryptophan (Trp) and beneficial indole-3-lactate (ILA) (Figure 2). The study also identified a new microbial metabolic pathway involving tryptophan synthase β subunit (TrpB) and aromatic lactate dehydrogenase (ALDH) in the conversion process (Figure 3), highlighting the sophisticated mechanisms by which specific HRB strains contribute to gut health. (Graphic: Business Wire)

Morinaga Milk’s New Research Breakthrough Backed the Superiority of its Human-Residential Bifidobacteria (HRB) Strains in Metabolizing Toxin Precursor in the Gut

Bifidobacterium infantis M-63 is a unique probiotic strain of human-residential bifidobacteria (HRB) – bifidobacteria that naturally reside in the human gut – and is renowned for its ability to utilize human milk oligosaccharides (HMO) found in breast milk, significantly improving the intestinal environment of healthy full-term infants. (Graphic: Business Wire)

Morinaga Milk Obtains the Registration of "New Food Ingredient" in China for use of its Probiotic Bifidobacterium infantis M-63 in Infant Foods

PR Newswire associated0

Glac Biotech Secures U.S. Food and Drug Administration GRAS Approval for Probiotic Strain CP-9